Trials / Completed
CompletedNCT00380588
Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer
A Randomized Study of Gemcitabine/Cisplatin Versus Single-Agent Gemcitabine in Patients With Biliary Tract Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To investigate efficacy and safety of gemcitabine combined with cisplatin and of gemcitabine alone by comparison in patients with advanced biliary tract cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | gemcitabine | 1000 milligrams per square meter (mg/m2), intravenous (IV) |
| DRUG | cisplatin | 25 milligrams per square meter (mg/m2), intravenous (IV) |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2006-09-26
- Last updated
- 2009-11-20
- Results posted
- 2009-11-19
Locations
7 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00380588. Inclusion in this directory is not an endorsement.